Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers

Myocyte Enhancer Factor 2 (MEF2) mediates cardiac remodelling in heart failure (HF) and is also a target of β-adrenergic signalling, a front-line treatment for HF. We identified global gene transcription networks involved in HF with and without β-blocker treatment. Experimental HF by transverse aort...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobin, S. W., Hashemi, S., Dadson, K., Turdi, S., Ebrahimian, K., Zhao, J., Sweeney, G., Grigull, J., McDermott, J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493616/
https://www.ncbi.nlm.nih.gov/pubmed/28667250
http://dx.doi.org/10.1038/s41598-017-04762-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493616/
https://www.ncbi.nlm.nih.gov/pubmed/28667250
http://dx.doi.org/10.1038/s41598-017-04762-x

Ejemplares similares